Visudyne 15

Visudyne 15


يسودين 15
Eye and Ear Preparations
category: use to Eye ،
concentration: 15mg

what medicine Visudyne 15؟

Verteporfin is a photosensitiser used in the photodynamic therapy of neovascular (wet) age-related macular degeneration . Following intravenous administration verteporfin accumulates preferentially in the endothelial cells of actively growing blood vessels, including those in the choroid. When activated by laser light it produces local vascular occlusion and this inhibits neovascularisation and reduces the decline in visual acuity.
Dosage: It is given by intravenous infusion over 10 minutes at a dose of 6 mg/m2. This is followed 15 minutes after the start of the infusion by activation using a laser tuned to a wavelength of
689 nanometres and delivered to the eye via a fibre optic device and a slit lamp, together with a suitable contact lens. The recommended light dose is 50 J/cm2, given over 83 seconds. Therapy may be repeated every 3 months for recurrent choroidal neovascular leakage. Verteporfin:investigated in the hotodynamic thera y of a variety of other disorders including malignant neoplasms.

what scientific name Visudyne 15؟

what form Visudyne 15؟

Vial

what company Visudyne 15؟

Esco/Switzerland

what price Visudyne 15؟

5161 EGP

what company Visudyne 15؟

Esco/Switzerland

what company Visudyne 15؟

Esco/Switzerland

Verteporfin is a photosensitiser used in the photodynamic therapy of neovascular (wet) age-related macular degeneration . Following intravenous administration verteporfin accumulates preferentially in the endothelial cells of actively growing blood vessels, including those in the choroid. When activated by laser light it produces local vascular occlusion and this inhibits neovascularisation and reduces the decline in visual acuity.
Dosage: It is given by intravenous infusion over 10 minutes at a dose of 6 mg/m2. This is followed 15 minutes after the start of the infusion by activation using a laser tuned to a wavelength of
689 nanometres and delivered to the eye via a fibre optic device and a slit lamp, together with a suitable contact lens. The recommended light dose is 50 J/cm2, given over 83 seconds. Therapy may be repeated every 3 months for recurrent choroidal neovascular leakage. Verteporfin:investigated in the hotodynamic thera y of a variety of other disorders including malignant neoplasms.


Note: All the provided information about this drug does not substitute for consulting a doctor.

Related tags

Related medicines